Innovation driven, rich development pipeline Where innovation shapes healthcare solutions:
Zydus AHL’s unique strength to provide newer solutions to meet the need of the veterinary farming communities in India, has been possible through in house development of new products as well as through global tie ups.
Pharmacology Technology Center (PTC) – of the Zydus Group supports new product development of Zydus AHL. The Centre undertakes development of novel deliveries & conducts stability & toxicological studies as a part of product development. Spearheaded by nearly 400 scientists, the Pharmaceutical Technology Centre has an ultra-modern & a highly accredited world-class facility, equipped for development of all types of dosage forms.
Zydus Research Centre (ZRC) –
The Zydus Research Centre (ZRC) is the dedicated research arm of the Zydus Group, spearheading the group’s research of NCEs. ZRC is working on cutting edge technologies in different scientific disciplines to discover novel therapeutic agents. The centre has capabilities to conduct drug discovery & development from concept to IND enabling preclinical and clinical studies.
In 2013, Zydus launched India’s first NCE research product LipaglynTM (Saroglitazar). This is a novel drug to treat diabetic dyslipidemia – a global unmet healthcare need. Today more than 10 lakh patients are on this drug. Continuing its work on Saroglitazar, Zydus’ researchers looked at possibilities to use the drug in the treatment of Non-Alcoholic Steatohepatitis (NASH), PBC (Primary Biliary Cholangitis) and Non Alcoholic Fatty Liver Disease (NAFLD) in women with Polycystic Ovarian Syndrome (PCOS). In March 2020, when the Drug Controller General of India approved Saroglitazar in India, it became the first drug anywhere in the world to be approved for the treatment of NASH.
The other global firsts from its research pipeline are the world’s first biosimilar of Adalimumab ‘Exemptia’, which brought freedom from pain to almost 15 million people in India suffering from inflammatory arthritis, including rheumatoid arthritis. TwinRab, the novel biologic developed in collaboration with WHO, is a one of its kind cocktail of two monoclonal antibodies which gives post – exposure prophylaxis after a rabid animal bite. This when taken with a vaccine offers complete protection from rabies.
With over 17 million suffering from Chronic Kidney Disease or CKD, this is a huge heath burden in India. In this condition, the kidneys fail to produce Erythropoietin (EPO) and this leads to low levels of haemoglobin (Hb) in the blood or anemia. The researchers from Zydus have developed Desidustat is a novel, oral HIF-PH inhibitor for treating this condition.
In February as the novel Coronavirus outbreak began to spread, Zydus launched a vaccine development programme to develop a plasmid DNA vaccine to fight COVID 19. ZyCoV-D has been developed entirely through in-house efforts and has successfully completed pre-clinical studies and also dosing of volunteers in its Phase I clinical trial. The vaccine has been found to be safe and well-tolerated. The phase II clinical trials for ZyCoV-D have now commenced.
A team of over 1400 scientists are engaged in drug discovery & development both for Human as well as Animal health segment. ZRC constantly focusses on selection and development of newer probiotic strains, application of phagebiotic and microbiome innovation. We look forward to build innovation driven strong product pipeline as an alternative solutions to medicated feed additives MFAs).